Relationship Of FEF₂₅₋₇₅, Pefr And SVC With Estrogen And Progesterone Level In Postmenopausal Women

Zinnat Ara Polly¹, Shelina Begum², Sultana Ferdousi³, Noorzahan Begum⁴, Taskina Ali⁵, Afroza Begum⁶

Abstract

Background: Deterioration of lung function is common in women after menopause, which may be related to very low estrogen and progesterone level. **Objective:** To observe FEF_{25,75} PEFR and SVC (slow vital capacity) values in apparently healthy postmenopausal women to find out their relationships with serum estrogen and progesterone. Methods: This study was carried out in the Department of Physiology in BSMMU, Dhaka in the year 2007. 30 healthy postmenopausal women aged 45 to 60 years and 30 healthy premenopausal women aged 20 to 30 years during their different phases of menstrual cycle were studied. Postmenopausal women were residents of Dhaka city and premenopausal subjects were medical students. FEF_{25-75.} PEFR and SVC of all subjects were measured by a digital micro spirometer. Their estrogen and progesterone levels were estimated by Micro particle Enzyme Immunoassay (MEIA) method. Data were analyzed by Pearson's correlation coefficient test, one way ANOVA and unpaired 't' test **Results:** The mean percentage of predicted values of FEF₂₅₋₇₅ and PEFR were lower in postmenopausal women compared to those of follicular and luteal phases of premenopausal women but it was not significant. Measured values of SVC was Significantly (p<.001) lower in postmenopausal women compared to those of follicular and luteal phases of premenopausal women. Again Mean serum estrogen and progesterone levels were significantly (p<.001) lower in post menopausal women compared to those of follicular and luteal phases of premenopausal women. In post menopausal women, $\text{FEF}_{25\text{--}75}$ was positively, PEFR and SVC were negatively correlated with progesterone level. PEFR and SVC showed positive correlattion and FEF₂₅₋₇₅ showed negative correlation with serum estrogen level. All these correlations were statistically non significant. In premenopausal women FEF_{25,75} and PEFR showed positive correlation and SVC showed negative correlation with serum progesterone level. The relationships were statistically significant in luteal phase but nonsignificant in follicular phase. FEF₂₅₋₇₅, PEFR and SVC were positively correlated with serum estrogen level in luteal phase but FEF₂₅₋₇₅ and PEFR negatively correlated and SVC positively correlated with estrogen level in follicular phase. Conclusion: The outcome of this study shows FEF₂₅₋₇₅ PEFR and SVC may be reduced in postmenopausal women which in turn may be associated with their low progesterone and estrogen levels.

Key words: Menopause, Lung function, Estrogen, Progesterone.

J Bangladesh Soc Physiol. 2011 December; 6(2): 116-121
For Authors Affiliation, see end of text.
http://www.banglajol.info/index.php/JBSP

Introduction



new hormonal pattern is established at menopause which is characterized by high levels of FSH, LH and very low

Received September 2011; Accepted December 2011

levels of estrogen and progesterone¹. In postmenopausal women, in addition to recognized complications, lung functions are also affected.² Several studies reported about

hyperventilation and bronchial relaxation associated with high progesterone during luteal phase.³⁻⁴ Sex hormones plays an important role in women's lung health⁵. It has also been observed that there is a close relationship between female sex hormones and lung function in postmenopausal women⁶. There is evidence that FEF₂₅₋₇₅ and PEFR were significantly lower in postmenopausal women compared to premenopausal women. Again decreased FEF25-₇₅ and PEFR in postmenopausal women are improved following hormone replacement therapy (HRT) 9-12 Large percentage of postmenopausal women in our country draws poor attentions of existing health care services and suffers from poor lung functions related complications. In postmenopausal women, relationship between low level of estrogen and progesterone and the changes in FEF₂₅₋₇₅ and PEFR have been explored by several investigators of different countries 10-12. But no published data on these parameters are available in our country. On the other hand no published data is available on SVC in postmenopausal women. Therefore, the present study attempted observe the FEF₂₅₋₇₅, PEFR and SVC in pre and postmenopausal women and to evaluate their relationship with serum estrogen and progesterone levels in these group of women.

Methods

This cross sectional study was carried out in the Department of Physiology in BSMMU, between January to December 2007. Protocol of this study was approved by ethical review committee of the department. 30 healthy postmenopausal women, aged 45-60 years (group B) and 30 premenopausal women, aged 20-30 years (group A) were enrolled .All the postmenopausal women were residents of different areas in Dhaka city and premenopausal women were students of a non government medical college, Dhaka. The postmenopausal subjects were assessed once and premenopausal women were assessed 2 times during follicular and luteal phase of menstrual

cycle. The premenopausal subjects were suggested to visit twice within 9th-14th days and 16th-23 th days after the beginning of last menstrual period. Subjects with history of chronic obstructive lung diseases, smoking, hypertension, cardiovascular diseases, diabetes mellitus, BMI > 22.9 kg/m², menstrual abnormalities, history of hormone replacement therapy, psychiatric disorders, head trauma with concussion and alcohol users were excluded. Before examination, the aims, objectives and benefits of the study were explained to all the subjects and their informed written consent were taken. Detail personal, medical and family history were taken. Thorough physical examinations of each subject were done. All these information were recorded in a prefixed questionnaire. For assessing lung function, $\ensuremath{\mathsf{FEF}}_{25\text{--}75}$, PEFR and SVC were measured at normal room temperature by using computer based digital Spirometer in the lung function laboratory of the Physiology department, BSMMU. 5ml blood was collected under aseptic precaution for estimation of estrogen and progesterone level. Serum estrogen and progesterone level were assessed by Micro particle Enzyme Immunoassay (MEIA) method in the laboratory of the Biochemistry department, BSMMU. Data analysis was done by using SPSS windows package version 12. unpaired t' test and Pearson's correlation coefficient test was performed for statistical significance.

Results

Mean serum estrogen level was significantly lower in group B compared to group A_2 and that of A_3 but it was higher in group A_2 than that of group A_3 but not significant. Again mean serum progesterone level in group B was significantly lower than that of A_3 but not than that of A_2 . The value of progesterone was significantly (p<0001) higher in group A_3 than that of A_2 (Table I).

Table I: Mean± SD Serum estrogen and progesterone levels in different groups (n= 60)

Groups	Estrogen	Progesterone		
	(Pgm/ml)	(ngm/ml)		
$A_2(n=30)$	155 ± 69.03	0.85 ± 0.60		
A_3	138.20 ± 56.73	11.12 ± 3.92		
B(n=30)	21.93 ± 10.46	0.20 ± 0.15		

Statistical analysis

Groups	p values	
A_2 vs A_3	0.204 ns	0.000***
B vs A_2	0.000***	0.275 ^{ns}
B vs A ₃	0.000***	0.000***

In group B, mean measured value of SVC was significantly(p<0001) lower and the mean of the percentage of predicted values of FEF $_{25-75}$ and PEFR were lower but not significant than those of group A_2 and A_3 (Table II).

FEF 25-75 was positively correlated with serum progesterogene level in group A2, A3 and B but it was statistically significant (p<0.01) only in group A3.

PEFR showed positive correlation with serum progesterone level in group A2, A3 but correlates negatively in group B and it was significant in group A3. SVC was negatively correlated in group A2 and B but positively and significantly correlated in group A3.

Table II: Mean percentage of predicted values of FEF ₂₅₋₇₅, PEFR and Measured value (Litre) of SVC in different groups (n=60)

Groups	FEF ₂₅₋₇₅ %	PEFR%	SVC(L)
$\overline{A_2}$	87.34 ± 10.86	64.24 ± 8.18	1.91±0.29
A_3	86.99 ± 12.54	66.08 ± 7.94	2.05 ± 0.89
В	84.48 ± 14.99	63.81 ± 7.94	1.57±0.30

Statistical Analysis

Groups	P values		
A_2 vs A_3	0.923 ^{ns}	0.338 ns	0.001**
B vs A_2	0.420 ns	0.823 ^{ns}	0.002**
B vs A ₃	0.478 ns	0.238ns	0.001**

 A_2 = follicular phase A_3 = luteal phase B= Postmenopause (study group)

***= p<0.001

FEF ₂₅₋₇₅ was positively correlated with serum estrogen level in group A3 but negatively correlated in group A2 and B wheres PEFR showed positive correlation in group A3 and B but negatively correlated in group A2. The relationship were statistically non significant.

SVC was positively correlated with serum estrogen level in group A2, A3 and B. The relationship was statistically significant in group A3 only.(Table III))

Table III: Relationships of serum estrogen and progesterone level with lung function parameters in different groups (n=60)

Parameters	Group A2		Group A3		Group B	
	Estrogen	progesterone	Estrogen	progesterone	Estrogen	progesterone
	r value	r value	r value	r value	r value	r value
FEF ₂₅₋₇₅	- 0.073 ^{ns}	+0.307 ns	+0.132ns	+0.369*	- 0.070 ^{ns}	+0.192ns
PEFR	-0.011 ^{ns}	+0.131 ^{ns}	+0.324ns	+0.369*	+0.050ns	-0.033 ^{ns}
SVC	+0.137ns	-0.06 ^{ns}	+0.435*	+0.38*	+0.141 ^{ns}	-0.124 ^{ns}

^{*=}p<0.05

Discussion

In this study, serum estrogen and serum progesterone level was significantly lower in postmenopausal women compared to premenopausal women.

In postmenopausal women, serum progesterone level was significantly lower compared to its value during luteal phase in premenopausal women. This finding was in agreement with some other investigators 15-17. In postmenopausal women, serum estrogen level was significantly lower than those during both follicular and luteal phases in premenopausal women. This observation was in agreement with those 18 who have demonstrated significantly lower estrogen level in postmenopausal women in comparison to that of follicular phase of menstrual cycle. However no such data is available to compare luteal phase. In this study, lower value of FEF 25-₇₅ and PEFR in postmenopausal women could not be compared due lack of data availability of published data.. The mean measured value of SVC was significantly lower in postmenopausal women than those of different phases of menstrual cycle in premenopausal women.

In postmenopausal women, FEF 25-75 was positively correlated with estrogen but negatively with progesterone. Again PEFR and FEF 25-75 both were negatively correlated with progesterone. SVC was positively correlated with serum estrogen level in postmenopausal women and premenopausal women. On the other hand SVC was negatively correlated with serum progesterone level in postmenopausal women and follicular phase of premenopausal women but positively correlate in luteal phase of premenopausal women. Various mechanisms have been proposed for these observed changes in lung function in postmenopausal women.. During menopause the ovaries become less functional and produce lower amounts of estrogen and progesterone ¹. Some investigators suggested that Progesterone induces hyperventilation through both the central

medullary and peripheral chemoreceptors⁶. Again, estrogen and progesterone have been associated with relaxation of airway smooth muscle in human model and thereby induce a relaxation of bronchial muscle 19 and bronchi are widened ²⁰. The bronchial epithelium and smooth muscle contain â2 adrenergic receptors and the â2 receptors mediate bronchodilatation and increase secretion ².Progesterone have a beneficial effects on the upper airway function and breathing is supported by pharyngeal dilator muscle activity 21. All these effects are contributed by estrogen and progesterone to increase lung function. Estrogen increases the number of progesterone receptors, therefore, combining effect of estrogen with progesterone increases lung function ²² .Adult women have less bone mass density and after menopause they initially lose it more rapidly ²³. The cause of the bone loss after menopause is primarily due to estrogen deficiency ²⁴. As there is decrease level of estrogen in post menopausal women it also decreases the bone mass density in the bones of thoracic cage and thus compresses the bones of thoracic cage ². Due to deformities of bones of the thoracic cage there is decrease in intrathoracic space which is related to decreased lung function 25. Various investigators suggested that estrogen and progesterone cause increase in muscle strength and induce skeletal myoblast growth 26 Decrease estrogen and progesterone levels decrease strength of respiratory muscle. However, the exact mechanisms involved for lower lung function in postmenopausal women of the present study cannot be elucidated from this type of study. According to the suggestions made by different investigators¹⁰⁻¹¹, lower percentage of predicted values of FEF ₂₅₋₇₅ PEFR and SVC in postmenopausal women in comparison to premenopausal women during follicular and luteal phase are most likely due to decreased level of progesterone and estrogen as observed in this study. Reduced levels of estrogen and progesterone would cause increased

compression of thoracic spine, decreased relaxation of bronchial smooth muscle and decreased muscular strength, and as a result there is decreased levels of FEF ₂₅₋₇₅ PEFR and SVC.

Conclusion

It may be concluded that reduced lung function in postmenapausal women may be related to their low estrogen and progesterone level.

Acknowledgements

The authors thank the participants of this study. This study was supported partly by research grant from University grant commission (UGC) of Bangladesh.

Authors Affiliation

- Zinat Ara Polly, Assistant Professor, Department of Physiology, Ibrahim Medical College,122, Kazi Nazrul Islam Avenue, Shahbagh, Dhaka-1000, Bangladesh. Email :zapimc@yahoo.com
- Shelina Begum, Professor and Chairman, Department of Physiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh.
- Sultana Ferdousi, Associate Professor, Department of Physiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh.
- Noorzahan Begum. Professor of Physiology Department of Physiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh.
- Taskina Ali , Associate Professor, Department of Physiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh.
- Afroza Begum , Assistant Professor (cc) Department of Community Medicine. Shaheed Suhrawardy Medical College

References

- ParhamC. Heart Spring 20007 [internet] [cited 2007 June 4) available from: http://www.Heart spring.net>
- Ganong WF. Review of Medical Physiology 2005;22nd edn. USA: McGraw-Hill;.
- Manson EJ, Marti AK. Postmenopausal hormone-Replacement Therapy, New Eng J Med 2001; 345(1): 34-40.
- Balzano G, Fuschillo S, Mellilo G, Bonini S. Asthma and sex hormones. Allergy 2001; 56 (1): 13-20.
- Kaygisiz Z, Erkasap N, Soydan M. Cardiorespiratory responses to submaximal incremental excersie are not affected by night's sleep derprivation during the follicular and luteal phases of the menstrual

- cycle. Indian J Physiol pharmacol 2003; 47 (3): 279-287.
- Pai RS, Prajna P, Urban JA, D'Souza. UJA. Correlative study iob blood pressure and lung function profiles during different phases of menstrual cycle among Indian population. Thai J Physiol Sci 2004; 17 (2): 30-34.
- Troisi RJ, Speizer FF, Willet MC, Trichopoulus D, Rosner B. Menopause, Postmenopausal estrogen preparations and risk of adult-onset asthma, Am J Respir Crit Care Med 1995; 152: 1183-1188.
- Real FG, Svanes C, Omenaas, RC, Anto MJ, Plana E. Lung function, respiratory symptoms and menopausal transition, J Allergy Cclin Immunol 2007; Article in Press.
- Catherine L, Carlson M, Cushmen PL, Enright L, Cauley A, Anne B. Newman. Hormone Replacement Therapy is Associaated with Higher FEV₁ in Elderly Women, Am J Resp and Crit Care Med 2001; 163: 423-428.
- Pata O, Atis SA, Utku OZ, Gurka Y, Ekren T, Cengiz P, Filiz K, Hander C, Meral A. The effect of hormone replacement therapy type on pulmonary functions in postmenopausal women, Maturitas 2003; 46: 213-218.
- Cevrioglu AS, Fidan F, Metimet U, Yilmazer M,Orman A, Ibrahim V, Serfeserm. The effects of hormone therapy on pulmonary function tests in post menopausal women, Maturitas 2004; 49: 221-227.
- 12. Koksal N, Guven A, Celik O, Kiran G, Kian H, Ekerbicer HC. The effect of Hormone replacement therapy an pulmonary functions in post menopausal women. Tuber Turkish 2004; 52 (3):237-42.
- Choi W, Pai SH. Association between respiratory function and osteoprosis in pre-and postmenopausal women. Maturitas 2004; 48: 253-8.
- World Developent Report, World Bank. Investing in Health 1993, Oxford University Press, New York.
- Lyons HA, Tang H. Therapeutic use of progesterone in alveolar hypoventilation associated with obesity, Am J med 1968; 44: 881-8.
- Hassan AAK, Carter G, Tooke JE. Postural vasoconstriction in women during the normal menstrual cycle Clin sci. 1990; 78: 39-47.

- Edwards N, Wilcox OJ, Sullivan GE. Hypercapnic blood pressure response is greater during the luteal phase of the menstrual cycle, J Appl Physiol 1946; 81: 2142-6.
- Fadel PJ Wang Z, Watanabe H, Arbique D, Vongpatana SW, Thomas GD. Augmented Sympathetic vasoconstriction in exercising forearms of postmenopausal women is reversed by estrogen J Physiol 2004; 561(3): 893-901
- Foster PH, Goldie RG, Paterson JW. Effects of steroid on beta-adrenoceptor- mediated relaxation of pig bronchus, Br J pharmacol 1983; 78: 441-5.
- Wikipedia Progesterone. The free encyclopedia.
 2007
- Popovic RM, White DP. Upper airway muscle activity in normal woman: Influence of hormonal status 1998 J Appl Physiol; 84:1055-1062

- Leavitt WW, Blaha GC. An estrogen-stimulated, progesterone-binding system in the hamster uterus and vagina, steroids 1972; 19: 263-274.
- Villareal RA, Civitelli R. Estrogen action on bone mass of postmenopausal women is dependent on body mass and initial bone density, J clin Endocrinol and Metab.1995; 80 (3): 776-782.
- Lindsay R, Aitken JM, Anderson JB, Hart DM, Mc Donald EB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by estrogen. Evidence for an increased bone mass after delayed onset of estrogen treatment. Lancet 1976;1:1038-1041
- Ross M, Marti G, Ricordi L, Farnasari G, Fratino P, Bernardi L. Cardiac autonomic dysfunction in obese subjects, Clin Sci. 1989; 76: 567-72.
- Kahlert S, Grohe C, Karas RH, Lobbert K, Neyses L, Vetter H. Effects of estrogen on skeletal myoblast growth, Biochem Biophys Res Commun 1997; 232: 373-8.